This page provides Relative Strength Index reference data for Biotechnology Fund Class, calculated from historical daily prices. The forecast output and associated deviation metrics are shown for informational use.
Biotechnology Fund's Relative Strength Index reference data is provided for informational and analytical purposes and does not constitute a trading recommendation.
Relative Strength Index Analysis Today
Biotechnology Fund Class has current Relative Strength Index of 42.48.
On March 18 2026 Biotechnology Fund Class was traded for 42.04 at the closing time. The highest daily price throughout the period was 42.04 and the lowest price was 42.04 . There was no trading activity during the period 1.0. Lack of trading volume on 03/18/2026 did not affect price variability. The overall trading delta to current closing price is 0.00% .
The price movement of Biotechnology is a central concern for all potential investors, regardless of their level of expertise. Biotechnology Mutual Fund price charts can be difficult to interpret due to the noise present in the data.
The following equities are related to Biotechnology Fund within the Health space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Biotechnology Fund against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
Market strength indicators applied to Biotechnology Fund mutual fund help investors assess the relative momentum and resilience of the security in different market environments. By using these indicators, traders can make more informed decisions about when to buy or sell Biotechnology Fund Class.
Risk indicator analysis for Biotechnology Fund is essential for accurately projecting its future price trajectory. By identifying the level of risk embedded in Biotechnology Fund's investment, investors can make informed decisions about position sizing and risk mitigation.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Biotechnology Fund
The amount of media and story coverage tied to Biotechnology Fund Class can signal where market attention is concentrating at the moment. Used properly, this context can help investors judge whether visibility is reinforcing the thesis or attracting more speculative pressure.
